DE69534701D1 - Verfahren zur behandlung von entzündlichen gelenkerkrankungen - Google Patents

Verfahren zur behandlung von entzündlichen gelenkerkrankungen

Info

Publication number
DE69534701D1
DE69534701D1 DE69534701T DE69534701T DE69534701D1 DE 69534701 D1 DE69534701 D1 DE 69534701D1 DE 69534701 T DE69534701 T DE 69534701T DE 69534701 T DE69534701 T DE 69534701T DE 69534701 D1 DE69534701 D1 DE 69534701D1
Authority
DE
Germany
Prior art keywords
treatment
joint diseases
inflammatory joint
inflammatory
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69534701T
Other languages
English (en)
Other versions
DE69534701T2 (de
Inventor
Yi Wang
Louis Matis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of DE69534701D1 publication Critical patent/DE69534701D1/de
Application granted granted Critical
Publication of DE69534701T2 publication Critical patent/DE69534701T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/821—Chemistry: analytical and immunological testing involving complement factors or complement systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69534701T 1994-09-23 1995-09-21 Verfahren zur behandlung von entzündlichen gelenkerkrankungen Expired - Lifetime DE69534701T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31148994A 1994-09-23 1994-09-23
US311489 1994-09-23
PCT/US1995/012404 WO1996009043A1 (en) 1994-09-23 1995-09-21 Methods for the treatment of inflammatory joint disease

Publications (2)

Publication Number Publication Date
DE69534701D1 true DE69534701D1 (de) 2006-01-26
DE69534701T2 DE69534701T2 (de) 2006-10-19

Family

ID=23207113

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534701T Expired - Lifetime DE69534701T2 (de) 1994-09-23 1995-09-21 Verfahren zur behandlung von entzündlichen gelenkerkrankungen

Country Status (8)

Country Link
US (2) US20030175267A1 (de)
EP (1) EP0777474B1 (de)
JP (1) JP3971797B2 (de)
AU (1) AU3729295A (de)
CA (1) CA2198706C (de)
DE (1) DE69534701T2 (de)
ES (1) ES2252746T3 (de)
WO (1) WO1996009043A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608133D0 (en) * 1996-04-19 1996-06-26 Gemini International Holdings Diagnostic method and apparatus
PT1265929E (pt) 2000-03-23 2009-10-15 Genentech Inc Inibidores anti-c2/c2a de activação complementar
US20060241074A1 (en) * 2001-08-14 2006-10-26 The General Hospital Corporation Methods for treatment of pain
CA2457461C (en) * 2001-08-17 2013-12-24 Tanox, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
US6719443B2 (en) 2002-02-27 2004-04-13 Robert A. Gutstein Electrically illuminated flame simulator
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
ES2965283T3 (es) 2006-03-15 2024-05-28 Alexion Pharma Inc Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
KR101503540B1 (ko) * 2006-09-05 2015-03-17 알렉시온 파마슈티칼스, 인코포레이티드 항체 매개된 신경병증의 치료를 위한 방법과 조성물
AU2008214359B2 (en) * 2007-02-05 2014-01-16 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
US20090324585A1 (en) * 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
RU2768492C2 (ru) 2011-11-18 2022-03-24 Ридженерон Фармасьютикалз, Инк. Полимерные белковые микрочастицы
RS58503B1 (sr) 2012-02-20 2019-04-30 Swedish Orphan Biovitrum Ab Publ Polipeptidi koji se vezuju za humani komplement c5
WO2017218515A1 (en) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
EP3529618B1 (de) * 2016-10-19 2020-12-02 Alexion Pharmaceuticals, Inc. Verfahren zur quantifizierung von ungebundenem c5 in einer probe
ES2888904T3 (es) * 2016-10-19 2022-01-10 Alexion Pharma Inc Un método de cuantificación de C5a sin unir en una muestra
MX2020006113A (es) 2017-12-13 2020-08-24 Regeneron Pharma Combinaciones de anticuerpos anti-c5 y usos de las mismas.
WO2020053206A1 (en) * 2018-09-10 2020-03-19 Volution Immuno Pharmaceuticals Sa Coversin for use in the treatment of rheumatic diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2703764B2 (ja) 1986-04-28 1998-01-26 シータス オンコロジー コーポレイション 補体成分Ｃ５ａに対するモノクローナル抗体
US5173499A (en) * 1988-04-15 1992-12-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
SG52383A1 (en) * 1993-05-17 1998-09-28 T Cell Sciences Inc Compositions comprising complement related proteins and carbohydrates and methods for producing and using said compositions
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
EP0751787B1 (de) 1994-03-23 2005-01-12 Alexion Pharmaceuticals, Inc. Verfahren zur reduktion von fehlfunktionen des immunsystems und der hämostase während des extrakorporalen kreislaufs
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis

Also Published As

Publication number Publication date
JPH10506113A (ja) 1998-06-16
JP3971797B2 (ja) 2007-09-05
DE69534701T2 (de) 2006-10-19
WO1996009043A1 (en) 1996-03-28
ES2252746T3 (es) 2006-05-16
US20050226870A1 (en) 2005-10-13
CA2198706C (en) 2008-07-08
EP0777474A1 (de) 1997-06-11
US7279158B2 (en) 2007-10-09
CA2198706A1 (en) 1996-03-28
EP0777474A4 (de) 2000-07-26
AU3729295A (en) 1996-04-09
US20030175267A1 (en) 2003-09-18
EP0777474B1 (de) 2005-12-21

Similar Documents

Publication Publication Date Title
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE69624116D1 (de) Verfahren zur behandlung von allergischem asthma
DE69434672D1 (de) Verfahren zur behandlung von hühnereiern
ATE323500T1 (de) Verfahren und zusammensetzung zur behandlung von verzögerten allergischen reaktionen und entzündungskrankheiten
DE69509544D1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE69109583D1 (de) Verfahren zur Behandlung von entzündlichen Darmerkrankungen.
EP0785785A4 (de) Verfahren zur bekämpfung von mit neuropeptiden zusammenhängenden erkrankungen
EP0820467A4 (de) Verfahren zur behandlung von augenkrankheiten
DE69427774D1 (de) Kontinuierliches verfahren zur behandlung von nahrungsmitteln
DE69818648D1 (de) Verfahren zur behandlung keimblättriger pflanzen
DE69707033D1 (de) Verfahren zur Behandlung von Gasen die Organohalogenzusammensetzungen enthalten
DE69526796D1 (de) Verfahren zur inhibierung von pflanzenkrankheiten
DE69814467D1 (de) Verfahren zur prophylaktischen behandlung von mastitis
DE69626311D1 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
DE69937624D1 (de) Verfahren zur Behandlung von Metalloberflächen
EP0777474A4 (de) Verfahren zur behandlung von entzündlichen gelenkerkrankungen
DE69834578D1 (de) Verfahren zur behandlung von zementaufschlämmungen
DE69702997D1 (de) Verfahren zur Behandlung von verunreinigtem Aluminiumoxid
DE59209268D1 (de) Verfahren zur thermochemisch-thermischen behandlung von einsatzstählen
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE69936994D1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
ATE198751T1 (de) Azoderivate von 5-aminosalicylsäure zur behandlung von enzündlichen darmerkrankungen
DE69331992D1 (de) Verfahren zur hochaufreinigung von menschlichem serumalbumin
DE69328615D1 (de) Verfahren zur behandlung von viehhaltungsgülle
DE69607559D1 (de) Verfahren zur Behandlung von Phenolteer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition